Form 4: Abbott Laboratories Director Michael F. Roman Reports Acquisition of Stock Equivalent Units

Director Michael F. Roman reports acquisition of Abbott Laboratories stock equivalent units through director fees.

Summary

• On September 30, 2024, Michael F. Roman, a director of Abbott Laboratories, acquired 309 stock equivalent units.
• These units were obtained as director fees and are payable in cash generally at age 65 or upon retirement from the board.
• The stock equivalent units earn the same return as if the fees were invested in Abbott shares.
• The price of the stock equivalent units was $114.01.
• Following the transaction, Roman directly owns 4,338 derivative securities.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive as it reflects standard director compensation practices and alignment of interests.

Positives

• The acquisition of stock equivalent units reflects continued alignment of the director's interests with the company's performance.

Future Outlook

The stock equivalent units will be paid out in cash generally at age 65 or upon retirement from the board.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.

Stakeholder Impact

• The transaction provides transparency to shareholders regarding director compensation.

Key Dates